How 10x Genomics, Inc. stacks up

TXG · against 552 other Healthcare companies listed in US-listed

Overall

28/ 100

Near the bottom of its peers.

Ranked #458 of 553 · scores higher than 16% of peers

Bars: peers in each 10-point band of the overall score

70 peers with an overall score of 20–29, including TXG · Click a bar to see the companies

The four scores behind it

Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)

Valuation#313 of 589Score 8 / 100 · beats 3%Growth#328 of 455Score 37 / 100 · beats 28%Profitability#282 of 558Score 26 / 100 · beats 48%Risk#312 of 597Moderate relative risk · safety 40 · beats 48%

Ranking by overall score

Top 5 and the companies ranked around TXG

Rank	Company	Market cap	Overall	Valuation	Growth	Profitability	Risk
1	Arbutus Biopharma CorporationABUS · US-listed	595M USD	97	96	98	99	0 / 2
1	Q32 Bio Inc.QTTB · US-listed	261M USD	97	93	—	98	0 / 2
3	Lakefront Biotherapeutics NVLKFT · US-listed	2.1B USD	96	96	99	93	0 / 2
4	Innoviva, Inc.INVA · US-listed	1.5B USD	93	94	91	93	0 / 2
5	Zevra Therapeutics, Inc.ZVRA · US-listed	609M USD	91	95	99	99	0 / 2

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score